Galectin Therapeutics Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing galectin-targeting therapies for fibrotic disease and cancer. Its lead candidate is belapectin, focused primarily on MASH cirrhosis and prevention of esophageal varices. The filing covers the three months ended March 31, 2024. The company has no product revenue and has incurred operating losses since inception.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $8.054 million | $8.799 million | Down 8.5% |
| General and administrative expense | $1.594 million | $1.543 million | Up 3.0% |
| Total operating expenses | $9.648 million | $10.342 million | Down 6.7% |
| Net loss | $11.489 million | $11.527 million | Down 0.3% |
| Net loss applicable to common stockholders | $11.497 million | $11.527 million | Down 0.3% |
| Basic and diluted loss per share | $0.19 | $0.19 | No change |
| Net cash used in operating activities | $12.105 million | $10.793 million | Use increased $1.312 million |
Cash and cash equivalents were $23.555 million at March 31, 2024, compared with $25.660 million at December 31, 2023. The company received $10.0 million from a related-party convertible line of credit during the quarter, resulting in a net cash decrease of $2.105 million.
Total liabilities were $96.976 million, including $31.139 million of related-party convertible notes and $51.324 million outstanding under the related-party convertible line of credit. Stockholders’ equity was a deficit of $72.809 million. The company had $20 million of additional availability under two related-party credit facilities at March 31, 2024.
Operating expense metrics were approximately 100% operating-loss margin and no revenue-based profit margin because the company generated no revenue. The filing does not provide a meaningful gross margin.
Material changes versus the prior comparable period
- Research and development expense decreased by $745,000, primarily because of the timing of NAVIGATE trial expenditures; clinical activity costs declined while other research and development costs increased with additional personnel.
- General and administrative expense increased by $51,000, reflecting higher compensation and investor relations/business development costs, partly offset by lower stock-based compensation.
- Interest expense increased to $1.052 million from $460,000, primarily reflecting higher related-party debt balances and financing-related costs.
- Changes in the fair value of derivative liabilities produced $869,000 of expense in Q1 2024, compared with $769,000 in Q1 2023.
- Shares outstanding increased to 62,148,134 at March 31, 2024 from 61,852,914 at December 31, 2023. Potential dilution was substantial: 41.6 million potentially issuable shares were excluded from diluted loss per share because they were anti-dilutive.
Guidance, outlook, risks and unusual items
- Management expects an interim analysis of the Phase 2b/3 NAVIGATE trial in late Q4 2024. The trial is evaluating belapectin for prevention of esophageal varices in patients with MASH cirrhosis and portal hypertension.
- Management believes available cash and credit availability are sufficient to fund currently planned operations through at least May 15, 2025. Additional capital will be required thereafter, and there is no assurance that financing, partnerships or other transactions will be available on acceptable terms.
- On March 29, 2024, the company drew an additional $10 million under its existing related-party convertible line of credit. The draw bears interest at 6.62%, is convertible at $3.00 per share at the lender’s election, and resulted in the issuance of 200,000 warrants exercisable at $3.59 per share.
- On March 29, 2024, the company also entered into a supplemental related-party convertible credit facility of up to $10 million, available through March 31, 2025, with repayment due by March 31, 2026.
- On May 14, 2024, after quarter-end, the holder of the $10 million April 2021 Note irrevocably elected to convert principal and accrued interest into common stock at $5.00 per share effective April 16, 2025. The note remains outstanding and accrues interest until that date; no shares will be issued before maturity.
- The company’s principal risks include continued losses and no revenue, dependence on additional capital, clinical trial execution and outcome risk, regulatory uncertainty, inability to demonstrate safety or efficacy, intellectual-property risks, competition, stock-price volatility and potential delays from health emergencies or other external events.
- There were no significant pending legal proceedings. The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Timing and results of the NAVIGATE interim analysis expected in late Q4 2024.
- Cash runway assumptions, including the availability and terms of the related-party credit facilities and the need for financing after May 15, 2025.
- Outstanding related-party debt maturities, conversion terms and potential equity dilution from notes, credit lines, warrants, options and preferred stock.
- Impact of the April 2021 Note conversion election on future share count and debt balances.
- Whether clinical trial spending, enrollment, regulatory milestones and financing availability remain consistent with management’s stated plans.
- Valuation assumptions and volatility underlying the $1.873 million of derivative liabilities recorded at March 31, 2024.